Epratuzumab
- Generic Name
- Epratuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-57-5
- Unique Ingredient Identifier
- 3062P60MH9
- Background
Epratuzumab is a humanized monoclonal antibody derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). This agent may subsequently be well matched for use in oncology and the treatment of inflammatory autoimmune disorders, such as lupus.
- Indication
Investigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.
- Associated Conditions
- -
- Associated Therapies
- -
Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)
Phase 2
Completed
- Conditions
- First Posted Date
- 2002-09-09
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Amgen
- Registration Number
- NCT00044902
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath